Latest News

Germany lagging behind in stem cell research

Neural stem cell. Confocal microscopy image illustrating long-range organization for neurons (green) and nuclei (blue) within a developing neural construct. © University of Wisconsin, Photo: Michael Schwartz.


by tg

A new analysis comparing the amount of funding invested into stem cell research clearly demonstrates declining investment in Germany. In contrast, the US, the UK, Sweden and Japan have increased their investments into the future field.

According to a White Paper from experts of the German Stem Cell Network (GSCN), investments into stem cell research in Germany initially increased from €58.8m in 2009 to €71.3m in 2011 but then permanently decreased to €54.9m by 2014. In contrast, the UK government almost doubled the amount of money into stem cell research from €82.4m in the fiscal year 2010/11 to €169.2m in 2014/15. Whilst investments of the Japanese funding bodies remained constant (€65.1m) from 2009-2012, they rose to €91.2m in 2014 due to the new focus of government investment into applications of induced pluripotent cells (iPSCs).

Most funding, however, is available in the US: the NIH has increased its annual budget for stem cell research from €1,070m in 2011 to €1.400m in 2015. However, funding of the state of New York and the Californian CIRM added €40.5m and €270m annually from 2011-2015 to that amount, respectively.

The GSCN said that Germany ranked last in funding with €0.68/citizen behind Japan (0.72), Sweden (1.02), the UK (2.62), and the US (4.36). The European Federation of Pharmaceutical Industry Associations (EFPIA) and the European Commission have put a focus on creating stem cell resources for secondary drug screening within the Innovative Medicines Initiative. They underline the need for improved funding to exploit the potential of stem cells in drug screening and regenerative medicine.

Curevac withdraws MAA of CVnCoV

CureVac announced that it will focus on a second-generation mRNA vaccine candidate in collaboration with the British pharma major GlaxoSmithKline....

Sound Bioventures Fund I AB closes at €110m

According to cornerstone investor Novo Holdings, one third each of the €110m from the first closing is to be invested in drug development companies...

Novartis inks US-$1.3bn deal with Dunad Therapeutics

British start-up company Dunad Therapeutics has signed a collaboration and license agreement with Novartis AG to generate orally bioavailable...

Novartis AG executes licence option with Molecular Partners

Further results from the randomized, placebo-controlled Phase IIa EMPATHY trial in acute COVID-19 ambulatory patients suggest that Molecular...

European sustainability fund raises €200m

The efforts to shift away from an economy relying on fossil fuels towards a circular, bio-based economy are gaining momentum. Now, the European...

Early-stage ventures fighting AMR wanted!

The official application process for the Start-up competition @AMR Conference 2022 has started. Early-stage ventures fighting drug resistant...

Evotec goes for massive IPO on Nasdaq

The Hamburg-based company announced that it has commenced a public offering in the USA of up to 22,000,000 American Depositary Shares. The price of...